NAION & Sudden Hearing Loss with PDE5 Inhibitors
Non-arteritic ischemic optic neuropathy and sudden sensorineural hearing loss
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Labeled warnings on FDA-approved PDE5 inhibitors
Reference only. Not medical advice.
What can go wrong
NAION can cause permanent partial vision loss; men with prior NAION in one eye are generally advised against PDE5 inhibitors because of the risk to the fellow eye. Sudden hearing loss may be partial or, less often, permanent. Both are rare. The practical guidance is to discontinue and seek urgent evaluation if sudden vision or hearing change occurs after dosing.
This is something to take to a clinician. The Atlas can tell you what is known about naion & sudden hearing loss with pde5 inhibitors in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
PDE5 inhibitor labels carry warnings about two rare events: non-arteritic anterior ischemic optic neuropathy (NAION), a sudden loss of vision from impaired blood flow to the optic nerve, and sudden sensorineural hearing loss. The evidence is genuinely mixed. NAION is rare and shares risk factors (the 'disc at risk' anatomy, hypertension, diabetes, cardiovascular disease) with the same population that uses PDE5 inhibitors, making causality hard to isolate; some pharmacoepidemiologic studies have reported a transient increased risk shortly after dosing while others find no population-level signal. Sudden hearing loss reports led the FDA to add a label warning in 2007. Both are uncommon, but men are advised to stop the drug and seek care promptly if sudden vision or hearing loss occurs.
Rare, debated, and label-warned: sudden vision or hearing loss after a dose.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
The proposed mechanism for NAION involves impaired perfusion of the optic nerve head, potentially via PDE5-mediated vascular effects in an anatomically crowded ('disc at risk') nerve. For sudden hearing loss, a vascular/cochlear mechanism is hypothesized but unproven. In both cases the absolute risk is low and disentangling drug effect from the high baseline cardiovascular risk of the user population is the central scientific difficulty.
Why causality is contested
Men who take PDE5 inhibitors disproportionately have hypertension, diabetes, and vascular disease - the very conditions that independently cause NAION. A correlation between use and these events can therefore reflect the underlying population rather than the drug. Self-controlled case-series methods have tried to address this; results have been inconsistent, which is why labels warn without claiming proof of causation.
Safety in detail
- NAION may cause permanent partial vision loss
- Prior NAION is a relative contraindication
- Sudden hearing loss may be permanent
- Absolute risk low; causality unsettled
What people get wrong
Often said'Viagra causes blindness'
ActuallyNAION is rare and a causal link is not established; the population using these drugs already carries high baseline NAION risk factors. The honest statement is 'rare, label-warned, evidence mixed' - not 'causes blindness.'
Often said'The hearing warning means it's been proven dangerous to hearing'
ActuallyThe 2007 FDA warning was based on accumulated spontaneous reports, which establish an association worth flagging, not a proven causal rate.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
What we do not know
- Does PDE5 inhibition genuinely raise NAION risk, or does confounding by indication fully explain the association?
At a glance
- NAION
- Sudden, usually painless, often partial vision loss
- Hearing
- Sudden sensorineural loss, often unilateral, +/- tinnitus
- FDA hearing-loss warning
- Added 2007
- Evidence
- Mixed; confounded by shared risk factors
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about NAION & Sudden Hearing Loss with PDE5 Inhibitors. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
FDA labeling action on sudden hearing loss2007
FDA required a sudden-hearing-loss warning across the PDE5 inhibitor class based on post-marketing reports
Pharmacoepidemiologic NAION studies2010s
Self-controlled and cohort studies reported inconsistent findings - some a small transient post-dose risk, others no population signal